Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Hilton Pharma (Pvt) Limited.

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000136 262 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx262product presentations
G61generic molecules
DF9dosage-form groups
TA11therapeutic areas
PKR262current price records
REG175registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage98%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixHilton Pharma (Pvt) Limited.Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026Anti-infectives100 · 38%CNS & mental health75 · 29%Endocrine & metabolic23 · 9%Cardiovascular16 · 6%Hematology & thrombosis16 · 6%Oncology & immunology10 · 4%Gastrointestinal & hepatology10 · 4%Other therapeutic areas12 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioHilton Pharma (Pvt) Limited.Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026262presentationsTablet190 · 73%Capsule21 · 8%Injection20 · 8%Suspension12 · 5%Solution6 · 2%Syrup6 · 2%Other forms7 · 3%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionHilton Pharma (Pvt) Limited.Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026240comparable productsBelow market median32 · 13%Near market median92 · 38%Above market median116 · 48%Company median price position+4.7%Lowest-price equivalents25Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsHilton Pharma (Pvt) Limited.Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/hilton-pharma-pvt-limitedGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,39 shared64% overlapM/s. Genix Pharma (Pvt) Ltd.39 shared64% overlapCCL Pharmaceuticals (Pvt.) Ltd.37 shared61% overlapGenome Pharmaceuticals (Pvt.) Ltd,36 shared59% overlapHigh-Q Pharmaceuticals34 shared56% overlapGetz Pharma (Pvt) Limited32 shared52% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives100 products · 38%
CNS & mental health75 products · 29%
Endocrine & metabolic23 products · 9%
Cardiovascular16 products · 6%
Hematology & thrombosis16 products · 6%
Oncology & immunology10 products · 4%
Gastrointestinal & hepatology10 products · 4%
Vitamins, minerals & nutrition7 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antiepileptics31 products · 12%
Antivirals30 products · 11%
Antidiabetic medicines23 products · 9%
Antipsychotics23 products · 9%
Antimalarials21 products · 8%
Macrolide antibacterials12 products · 5%
Anticoagulants12 products · 5%
Calcium-channel blockers11 products · 4%
Formulation footprint

Dosage forms

Tablet190 products
Capsule21 products
Injection20 products
Suspension12 products
Solution6 products
Syrup6 products
Infusion4 products
Other2 products
Drops1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 LERACELevetiracetam 24presentations 100 mg/mL, 1000 mg, 250 mg, 500 mg · Solution, Tablet, Injection #2 REZCALMRisperidone 13presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #3 NOVIARibavirin 10presentations 200 mg, 400 mg, 500 mg, 600 mg · Tablet #4 RIVARRivaroxaban 10presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #5 XENGLUEmpagliflozin 10presentations 10 mg, 25 mg · Tablet #6 HifloxCiprofloxacin 8presentations 100 mg, 100 MG, 125 mg/5 mL, 200 mg/100 mL · Tablet, Infusion, Suspension
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3213% of comparable products
Near market median92within ±5% of median
Above market median11648% of comparable products
Lowest-price equivalents25ties included
Company median price position +4.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
CEFIM 400 mgCefixime · Tablet · 1x5's PKR 65.00/tablet-47.1% vs market median HILPEP 300 mgRanitidine · Tablet · 1X10's PKR 16.45/tablet-22.7% vs market median HILOMET XR 1000 mgMetformin · Tablet · 5x10's PKR 3.11/tablet-19.8% vs market median HILZIDE 80 mgGliclazide · Tablet · 2 × 10's PKR 8.85/tablet-16.9% vs market median XENGLU 25 mgEmpagliflozin · Tablet · 28's PKR 83.79/tablet-16.3% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 39shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 39shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 37shared generics Genome Pharmaceuticals (Pvt.) Ltd,149 products · 71 generics 36shared generics High-Q Pharmaceuticals196 products · 59 generics 34shared generics Getz Pharma (Pvt) Limited289 products · 64 generics 32shared generics
Regulatory & price activity

Observed database signals

Registration numbers175
Price-history records342
Products with price history45
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date4 Aug 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

100 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
AZIMYCIN Azithromycin 200 mg/5 mL Suspension 15ml 027060 PKR 330.48 PKR 22.03/mL Near median
AZIMYCIN Azithromycin 250 mg Tablet 6's 088215 PKR 281.65 PKR 46.94/tablet Near median
AZIMYCIN Azithromycin 500 mg Tablet 6's 088216 PKR 516.36 PKR 86.06/tablet Near median
AZIMYCIN Azithromycin 250 mg Capsule 6's 027059 PKR 311.04 PKR 51.84/capsule 7% above median
CEFIM Cefixime 400 mg Tablet 1x5's 135273 PKR 325.00 PKR 65.00/tablet 47% below median
CEFIM Cefixime 200 mg Tablet 1x10's; 2x5's 135274 PKR 314.00 — No comparator
CEFIM Cefixime 100 mg/5 mL Suspension 30ml 022108 PKR 365.33 PKR 12.18/mL 16% above median
CEFIM Cefixime 200 mg Capsule 10's 034664 PKR 661.02 PKR 66.10/capsule 5% above median
CEFIM Cefixime 400 mg Capsule 5's 019818 PKR 645.08 PKR 129.02/capsule 14% above median
CEFIM Cefixime 100 mg/5 mL Suspension 60ml 022108 PKR 766.09 PKR 12.77/mL 22% above median
CEFIM Cefixime 200 mg/5 mL Suspension 30ML 029082 PKR 447.19 PKR 14.91/mL 15% above median
CLAHIL Clarithromycin 125 mg/5 mL Oral drops 25ml 089136 PKR 174.61 PKR 6.98/mL 5% below median
CLAHIL DS Clarithromycin 250 mg/5 mL Dry suspension 60ml 081475 PKR 707.22 PKR 11.79/mL Near median
CLAHIL XL Clarithromycin 500 mg Tablet 5's 081474 PKR 396.73 PKR 79.35/tablet Near median
CLAHILTABLET Clarithromycin 250 mg Tablet 1 × 10's 027061 PKR 563.76 PKR 56.38/tablet 21% above median
CLAHILTABLET Clarithromycin 500 mg Tablet 1 × 10's 027062 PKR 1,030.32 PKR 103.03/tablet 25% above median
CLAVIR Daclatasvir 60 mg Tablet 28's 084762 PKR 9,267.83 PKR 330.99/tablet Near median
CLAVIR Daclatasvir 30 mg Tablet 28's 084763 PKR 5,223.31 PKR 186.55/tablet Near median
COLT Clarithromycin 125 mg/5 mL Suspension 60ml 027063 PKR 486.00 PKR 8.10/mL 12% above median
CRAVIT Levofloxacin 250 mg Tablet 10's 022245 PKR 865.92 PKR 86.59/tablet 82% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.